Abstract
Objective Healthcare professionals (HCPs) in cancer care often face patient deaths, yet there is a notable absence of comprehensive evidence regarding their grief. This scoping review seeks to identify key aspects of professional grief in cancer care and give an overview pertaining its’ conceptualization and frequency and intensity.
Methods The primary search covered three databases (PUBMED, PSYNDEX, and PsycINFO). Two independent reviewers assessed 2,248 records, selecting 34 eligible articles.
Results Most studies originated from North America and Israel, with limited evidence from the global south, East Asia and Europe, as well as few quantitative studies. HCPs exhibit classic grief symptoms (such as sadness) and distinct features (e.g., feelings of guilt) in response to patient deaths, though a clear definition and measures of professional grief are lacking. Grief frequency varies highly (from 23% to 100%).
Conclusions Future research should refine definitions and measures to better support HCPs in effectively managing professional grief in cancer care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.